Nasal Drug Delivery Market 2019 Analysis, Opportunities And Forecast To 2025

Market Scenario

The global nasal drug delivery market is expected to grow significantly over the forecast period. The global market was valued at approximately USD 52,998.5 million in 2018 and is projected to grow with 6.6% CAGR over the forecast period.

Nasal drug delivery is administration of drug through the nasal track to treat various respiratory problems such as paranasal sinuses, nasal infection, and other nasal problems. It is an effective delivery method for medicines that are active in low doses.

Factors such as the painless drug administration, development of new nasal drug delivery technology market, and the increasing number of patient population with respiratory problem are expected to drive the market growth. Moreover, nasal drug delivery devices are easily accessible and suitable for self-medication it has received positive response from patient population, clinicians, and pharmaceutical scientists. 

However, factors such as low bioavailability, nasal irritation, and irreversible damage of cilia of cell is expected to hamper the nasal drug delivery market.

Segmentation

The global nasal drug delivery market has been segmented into drug type, dosage form, basis of system, delivery technologies, therapeutic applications, end users, and region.

Based on drug type, the global market has been segmented into anesthetics, antibiotics, pain relief drugs, calcium supplements, vasoconstrictors, antihistamines, and others.

Based on dosage form, the global market has been segmented into drops, sprays, powder, gels, and ointments.

Based on the basis of system, the global nasal drug delivery market has been segmented into unit dose, multi-dose, and metered dose.

Based on delivery technologies, the global market has been segmented into spray, nebulizers, inhalers, and others.

Based on therapeutic applications, the global market has been segmented into rhinitis, asthma, nasal congestion, chronic obstructive pulmonary disease (COPD), cystic fibrosis, and others.

The global market, by end user, has been divided into home care settings and hospitals & clinics.

The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The nasal drug delivery market in the Americas has further been segmented into North America and Latin America, with the North American market divided into the US and Canada.

The European nasal drug delivery market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.

The Asia-Pacific nasal drug delivery market has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific.

The nasal drug delivery market in the Middle East & Africa has been segmented into the Middle East and Africa. The increasing development in healthcare infrastructure and growing economy in countries such as Kuwait, Iran, Israel, and Iraq drive the market growth in this region. 

Key Players

GlaxoSmithKline Plc. (UK), AstraZeneca (UK), Pfizer, Inc. (US), Becton Dickson & Company (US), Dr. Reddy’s Laboratories Ltd. (India), Sanofi-Aventis (UK), Merck & Co. (US), Cadila Pharmaceuticals (India), AEGIS THERAPEUTICS LLC (US), Novartis AG (UK) , Johnson & Johnson Services, Inc (US) and 3M COMPANY (US) are some of the key players in the global nasal drug delivery market.

Regional Market Summary

Geographically, the market has been segmented, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The Americas is anticipated to dominate the global nasal drug delivery market owing to an increasing prevalence of rhinitis, congestion, sinusitis, and respiratory allergic reactions.

Additionally, the well-developed healthcare sector and presence of a large number of medical device companies in this region boosts the market growth. According to the Centers for Disease Control and Prevention January 2017, 30.8 million adults were diagnosed with sinusitis in the US.

Europe is expected to hold the second-largest position in the global nasal drug delivery market. The presence of a large patient population suffering from chronic disorders, increasing technological advancement in the healthcare industry, and growing mergers and acquisitions between healthcare companies drives the market growth in this region.

Alabama Nasal Drug Delivery Association (ADMEA) is a Europe based non-profit organization involved in providing home medical equipment. The presence of such organization in Europe enhances the market growth during the forecasted period.

Asia-Pacific is expected to be fastest-growing region owing to the growing geriatric population and increasing incidences of allergy diseases, which is a common cause of respiratory problems in developing countries.

The Middle East & Africa holds the least share of the market. A majority of the market share of this region is expected to be held by the Middle East due to growing government initiatives for the healthcare sector in this region.

Cough Syrup Market Dynamics, Forecast, Analysis And Supply Demand 2019

Market Scenario:

The Global Cough Syrup Market Statistics expects to register a CAGR of 3.45% to reach USD 5,139.63 million by 2026. Cough syrups are the medication used for the temporary relief of coughs, sneezing, or runny noses due to the common cold, hay fever, or other upper respiratory allergies.

The increasing incidence of respiratory disorders along with the rising air pollution are some of the key factors contributing to the growth of the cough syrup market. Additionally, the growing geriatric population, along with an active pharmaceutical sector, are boosting market growth as aged people are more prone to respiratory disorders. Furthermore, the market is expected to witness lucrative growth due to increasing product developments.

However, product recalls, and the stringent regulatory scenario are hampering the growth of the Cough Syrup market.

Market Dynamics

Rising air pollution is acting as a driver for the growth of the market. Air pollution is a major environment-related health threat that stands as a risk factor for both acute and chronic respiratory diseases. According to a report by the Forum of International Respiratory Societies (FIRS), tobacco smoke, indoor air pollution from burning fuels, and air pollution from traffic and industrial sources are highlighted as the primary contributing factors for most respiratory conditions. World Health Organization (WHO) estimated that 4.3 million deaths per year could be attributed to indoor air pollution. Most diseases and deaths that can be attributed to prolonged exposure to poor indoor air quality occurs primarily in women and children, especially in low-income families. Exposure to indoor smoke used for heating and cooking leads to COPD, lung cancer, and, in children, it causes pneumonia and asthma. This large population affected with respiratory disorders due to air pollution is driving the market for cough syrup market as it is a crucial medicine used for the treatment of such diseases.

Segmentation

The global cough syrup market has been segmented into product type, category, and application. Based on product type, the market has been segregated into combination and individuals. Combination product type has been further classified as dextromethorphan + guaifenesin, guaifenesin + pseudoephedrine, and brompheniramine + pseudoephedrine. The individual product type has been further divided into dextromethorphan, guaifenesin, ambroxol, and codeine. Based on the category, the market has been segmented into cough suppressants and expectorants. And by application, the cough syrup market has been categorized as adults and children.

Regional Analysis

The global cough syrup market, based on region, has been divided into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The Americas is expected to hold a maximum share of the global cough syrup market, and the regional market is projected to register a CAGR of 3.16% during the forecast period. The presence of significant market players in the region, strategic acquisitions by major players to enhance product portfolio, increasing cases of respiratory disorders, and availability of advanced medications for the treatment of chronic obstructive pulmonary disease (COPD) is expected to drive the market growth in this region to combat these concerns effectively through the use of cough syrups.

Europe accounts for the second-largest, in the global cough syrup market, majorly due to the presence of key players such as Novartis, GlaxoSmithKline, and Reckitt Benckiser Group PLC. The cough syrup market in Europe is expected to be driven by the growth of the pharmaceutical industry in Germany, France, and the UK.

Asia-Pacific is estimated to be the fastest-growing market due to the continuous development in developing countries such as India and China. High prevalence of respiratory disorders due to tobacco smoke, exposure to air pollutants at home and the workplace, vehicular pollution, and indoor air pollution from biological agents related to damp and mold further increase the risk of respiratory disease in children and adults in these countries.

The Middle East & Africa cough syrup market has been segmented into major two regions, the Middle East and Africa. The developed countries in the region, such as the UAE and Saudi Arabia, are the ones with the maximum share of the cough syrup market. The advancing healthcare infrastructure, increasing healthcare expenditure, and increasing per capita disposable incomes of the people in these countries are some reasons leading to the large share of the market in these countries. Africa is the least developed region with limited healthcare resources and facilities for the people. The low growth rate due to less developed and less efficient health systems is hampering the growth of the market.

Key Players

The prominent players in the global cough syrup market are Pfizer, Inc. (US), Novartis AG (Switzerland), Merck KGaA (US), Johnson & Johnson Services, Inc. (US), GlaxoSmithKline PLC (UK), Acella Pharmaceuticals, LLC (US), Procter & Gamble (US), Reckitt Benckiser Group PLC (UK), Abbott (US), and Sanofi (France).

The players operating in the global cough syrup market are focusing on product launches, along with expanding their global footprints by entering untapped markets.

• In February 2019, Merck invested USD 70 million to expand its research & development (R&D) facility in Billerica, Massachusetts for the development of innovative clinical pipeline products.

• In July 2018, Johnson & Johnson acquired Zarbee's Naturals, a drug-free children's cough syrup. This enabled the company to broaden its product portfolio globally.

• In December 2016, Pfizer, Inc., launched a series of products as a line extension under the Corex brand name. The first launch was on December 2016, and subsequent launches were conducted in 2017. These formulations were duly approved by central and state regulators.Bottom of Form

Veterinary Imaging Market Expected To Grow At High Cagr During Forecast Period 2019 – 2023

Market Scenario

The Global Veterinary Imaging Market is expected to register a CAGR of 7.14% to reach USD 2167.78 million by 2025. Veterinary imaging is the noninvasive method that helps to diagnose disease by making medical images of the veterinary body. We have various advanced imaging technology used for veterinary patients. Veterinary imaging instruments are used to diagnosis of chronic disease and getting medical images of animals. Notably, the increasing prevalence of zoonotic diseases, significant rise in pet insurance purchases, and increased number of veterinary practitioners are promoting the growth of the veterinary imaging market globally.

The market growth is mainly driven by increasing incidence of zoonotic diseases, increasing expenditure on pet insurance, and technological advancements in veterinary imaging. However, high procedure cost and lack of skilled veterinarians may slow the growth of the market.

Market Dynamics

Increasing expenditure on the pet is driving the growth of the Veterinary Imaging market. Pet insurance covers various minor to major medical expenses such as accidents, chronic conditions, wellness, and routine care coverage, medication coverage, diagnostic testing and imaging, others. Though pet insurance does not provide 100% coverage, it reimburses around 80% of the total pet medical expenses. According to the North American Pet Health Insurance Association (NAPHIA), North America’s pet health insurance growth was exceeded by 17.2% from 2014 to 2015. It is also reported that the total number of insured pets reached 1.6 million at the end of 2015.

Pet owners spend a lot on routine vet expenses and surgical vet visits. As per the data suggested by The American Pet Products Association (APPA), around 65% of the US population owns a pet, and the US pet industry expenditure in 2015 was USD 60.3 million, which is exceeded to USD 62.8 million. Thus, with the growing spending on animal healthcare, the demand for veterinary diagnosis and the equipment required for the same will also increase, which boosts the growth and veterinary imaging market size.

Segmentation

The global veterinary imaging market is segmented into product type, animal type, therapeutic area, and end user. On the basis of product type, the market is segmented into instruments, veterinary imaging reagents, and veterinary software. On the basis of animal type, it is segmented into small companion animals and large animals. On the basis of the therapeutic area, the veterinary imaging market segmented into orthopedics and traumatology, cardiology, neurology, and oncology. On the basis of end user, the Veterinary Imaging market segmented into hospitals & clinics, and academic institutes.

Regional Analysis

The global veterinary imaging market, based on region, is divided into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The Americas accounted for the largest market share in 2018, and the regional market is projected to register a CAGR of 7.62% during the forecast period. The larger share is majorly attributed to the growth in adoption of pet animals, increasing veterinary healthcare expenditure, increasing demand for pet insurance, and increasing pet ownership. According to the report published by the American Pet Products Association, from 2017 to 2018, 68% of the US households or 85 million families have a pet.

Europe is the second-largest market for veterinary imaging owing to the presence of large market players, innovative advanced technology, increasing companion animal ownership, and the presence of veterinaries.

The Asia Pacific region accounted the third-largest market owing to the presence of large animal population, increasing disposal income, increasing nuclear families preferring to have pets and increased investments by the American and European market giants in Asian countries such as China and India. India held a share of 15.9% in the Asia-Pacific veterinary imaging market in 2018.

The market in the Middle East and Africa is constrained due to poor development of the animal industry and the low productivity of the maximum breeds in the region.

Key Players

The prominent players in the global veterinary imaging market are Esaote SpA (Italy), GE Healthcare (US), Medical Imaging/IMCO, Inc. (US), BCF (Scotland), Fujifilm Holding Corporation (Japan), Heska Corporation (US), Diagnostic Imaging System, Inc. (US), Canon Inc. (Tokyo), Carestream Health (US), and Merry X-Ray (US).

The players operating in the global veterinary imaging market are focusing on product launches, along with expanding their global footprints by entering untapped markets.

• In March 2019, Esaote SpA launched the new ultrasound platform MyLabX8 for increasing efficiency of ultrasound machines and to maintain the workflow.
• In October 2018, GE Healthcare announced a strategic collaboration with SonoSim to encourage education and training about ultrasound devices. This collaboration is likely to help the company to increase its customer base.
• In June 2018, Fujifilm Holding Corporation acquired Irvine Scientific Sales Company, Inc. for USD 800 million. With this acquisition, Fujifilm is likely to enter into the cell culture media business.

Immunoassays in R&D Market Trends, Analysis And Review During 2019 To 2023

Market Scenario

The Global Immunoassay In R&D Market is expected to register a CAGR of 8.18% and is anticipated to reach USD 475.3 million by 2023. Immunoassays are analytical methods in which the quantitation of the analyte depends on the reaction of an antigen and an antibody. Immunoassays incorporate a variety of different labels for the detection of antibodies and antigens. These labels are generally chemically linked or conjugated to the desired antibody or antigen.

The increasing incidence of chronic and infectious diseases, growing research and development investment (R&D) activities, and technological advancements are the major factors boosting the growth of the market. Despite the drivers, the high cost of immunoassay procedures and the high price of immunoassay systems constrain the growth of the market.

Market Players

Market Research Future (MRFR) recognizes the following companies as the key players in the global immunoassay in R&D market that includes Bio-Rad Laboratories, Inc. (US), Thermo Fisher Scientific Inc. (US), Siemens Healthineers (Germany), Becton, Dickinson and Company (US), Danaher Corporation (US), bioMérieux Inc. (France), Abbott Laboratories (US), F. Hoffmann-La Roche Ltd (Switzerland), Sysmex Corporation (Japan), and Abcam plc (United Kingdom).

Segment Analysis

The global immunoassay in R&D market has been segmented into type, application, and end user. By type, the market has been segmented into Enzyme-Linked Immunosorbent Assay (ELISA), Enzyme-Linked Immunospot Assay (ELISpot), Radioimmunoassay (RIA), Chemiluminescence (CLIA), Fluoroimmunoassay, and Others. On the basis of application, the market has been segmented into infectious diseases, cancer research, endocrinology, autoimmune diseases, and others. By end-user, the market has been segmented pharmaceutical and biotechnology companies, academic institutions and laboratories, and others

Regional Analysis

Geographically, the Americas is expected to dominate the global immunoassay in R&D market. The market growth is attributed to the increasing number of research projects in laboratories, growing adoption of advanced technology in research, and the growing prevalence of several diseases. The European market for immunoassay in R&D is expected to be the second-largest market due to the growing adoption in diagnostic measures is expected to boost the growth of the market in this region.

Moreover, the companies operating in the market are particularly focusing on mergers and acquisition which is expected to support the market growth. Asia-Pacific is estimated to be the fastest growing market due to the developing healthcare infrastructure and increasing disposable income. In addition to this, improving healthcare infrastructure has increased the number of research activities in the region. Moreover, in the Asia-Pacific region, South Korea accounted for a market share of 10.1% in 2017. Furthermore, the market in the Middle East & Africa is expected to witness steady growth due to limited access to healthcare facilities.

Key Findings of the Study:

• Global immunoassay in R&D market is projected to reach USD 3 million by 2023 with 8.18% CAGR during the review period of 2018 to 2023

• Americas accounted for the largest immunoassay in R&D market share in the region due to the increasing number of research projects and the growing prevalence of chronic diseases

• The pharmaceutical and biotechnology companies segment accounted for a market value of USD 174.3 million in 2017

Injectable Drug Delivery Devices Market - Demand, Growth, Opportunities And Analysis Of Top Key Player Forecast To 2023

Market scenario:

The Global Injectable Drug Delivery Devices Market is expected to register 11.3% CAGR and is anticipated to reach USD 17,401.8 million by 2023. Injectable drug delivery devices, including conventional syringes, needle-free injectors, and auto and pen injectors, have been extensively utilized for the administration of drugs to treat medical conditions ranging from cancer to autoimmune disorders. The global market for injectable drug delivery devices has witnessed continuously increasing R&D. As a result, the market is fragmented into various high-end and technologically advanced products. Following the illustrated course, it is projected that an increasing prevalence of chronic diseases, growing adoption of self-injectable devices, and rising FDA approvals drive the market growth. However, the presence of cross-contamination and increasing cost of high-end products are estimated to restrain the market growth during the forecast period.

Market Dynamics

The global injectable drug delivery devices prevalence of chronic diseases such as diabetes, heart diseases, multiple sclerosis, cancer, and arthritis have increased. According to the statistical report published by the American Diabetes Association, in 2017, ~30.3 million, i.e., 9.4% of the total population within the US had diabetes in 2015. Moreover, the fact sheet of 2018 published by the World Health Organization estimates cancer to be the second leading cause of death across the globe. The disease is estimated to cause ~9.6 million deaths in 2018. The other factors that are driving the global injectable drug delivery devices market are growing adoption of self-injectable devices, Rising FDA approvals for the drug delivery devices, and others.

Global Injectable Drug Delivery Devices Market Size, by Site of Delivery, 2017 & 2023 (USD Million)
Segmentation

The global Injectable drug delivery devices market has been segmented into devices, therapeutic application, usage pattern, site of delivery, distribution channel, and facility of use.

Based on device, the global market is divided into conventional injection devices and self-injection devices.

Based on therapeutic application, the global market is segmented into autoimmune diseases, hormonal disorders, and cancer.

Based on usage pattern, the global market is divided into curative pattern and immunization.

Based on site of delivery, the global market is segmented into intramuscular, subcutaneous, and intradermal.

Based on distribution channel, the global market is divided into hospital & retail pharmacies and online platforms.

Based on facility of use, the global market is segmented into hospitals and clinics and home care settings.

Key Players

The prominent players in the global Injectable drug delivery devices market are Eisai Co., Ltd, Antares Pharma, AstraZeneca, Becton, Dickinson and Company, Eli Lilly and Company, F. Hoffmann-La Roche AG, Johnson & Johnson Services Inc., Mylan N.V., Novartis AG, Novo Nordisk, Pfizer Inc., Sanofi, Teva Pharmaceutical Industries Ltd, and Inovio Pharmaceuticals Inc.

Regional Analysis

The global Injectable drug delivery devices market, based on region, is segmented into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.

The Americas is anticipated to dominate the global injectable drug delivery devices market owing to the rising awareness about the condition and high healthcare expenditure. The region is expected to reach USD 17,401.8 million by 2023 with a CAGR of 11.3% from2018 to 2023. The Americas accounted largest regional market owing to the growing biotechnology industry, the ever-increasing prevalence of cancer and diabetes, and a well-developed healthcare sector.  

Europe accounted for the second-largest market share in 2017 due to extensive R&D in healthcare, increasing funding, and growing adoption of the devices within the region.

On the other hand, the Middle East & Africa is expected to observe slow growth due to less exposure to healthcare services, lack of awareness, and stringent government rules and regulations.

Precision Medicine Market Volume Forecast And Value Chain Analysis 2019

The major market driving factor for precision medicine are patient’s involvement in personal healthcare, integration of wireless technologies with portable healthcare devices, and increase in genetic diseases (due to mutation, UV rays) among others.

The global precision medicine market was valued at $38.92 billion in 2015, and is expected to reach $88.64 billion by 2025. Thus the market is expected to perform a growth at a CAGR of 12.48% from 2015 to 2025.

Precision medicine evolved from the concept that same medicine cannot function equally for two different individuals with the same disease as they have different gene structure. At the same time, medication depends on how well patients can respond to its dosage. Hence, the need for precision medicine. Market Research Future (MRFR), in their report, has included various drivers and segments that can produce a reliable prediction for the future market. Prevalent diseases such as cancer, diabetes, and others are boosting the precision medicine market as treatment of such diseases gets a better result with personalized medicine structure. Furthermore, its impact can significantly lower the cost of treatment.

However, a personal data breach can be seen as a major precision medicine market growth prohibition. The diagnostic cost can incur a high cost, stringent government policies, the risk with hardware and software failure, and lack of medical framework can hold back the market during the forecast period.

Key Players for Global Precision Medicine Market:

Abbott Laboratories, Almac Group, Ltd., Asuragen, Inc., Biomérieux Sa, Cepheid Inc., Cetics Healthcare Technologies Gmbh, Ge Healthcare, Glaxosmithkline Plc, Johnson & Johnson, Laboratory Corporation Of America Holdings, Medtronic, Novartis, Pfizer Inc., Qiagen, Biobase Gmbh, Quest Diagnostics Inc, Randox Laboratories Ltd., Sanofi Pharma, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Ab-Biotics Sa, Caris Life Sciences, Healthcore, Inc., Ibm, Innventis, Intel Corporation, Molecular Health Gmbh, Precision For Medicine

Key Findings:

• The global precision medicine market is expected to reach USD 88.64 billion by 2025.
• By ecosystem diagnostic tool companies holds the largest market share of precision medicine market and is expected to reach USD 27.56 billion by 2025.
• By sub-market, company diagnostics holds the largest market share of precision medicine market and is expected to reach USD 21.32 billion by 2025.

Segmentation

The global precision medicine market has been segmented into ecosystem players, sub-markets, and therapeutics.

Based on ecosystem players, the global market has been segmented into pharmaceuticals and biotechnology companies, diagnostic companies, healthcare IT specialists/big data companies, and clinical laboratories. The diagnostic tool companies segment accounted for a market value of USD 16.27 million in 2017.

Based on sub-markets, the global market has been segmented into companion diagnostics, biomarker-based test, targeted therapeutics, pharmacogenomics (PGX), molecular diagnostics, and others.

Based on therapeutics, the global market has been segmented cancer/oncology, cardiovascular disease (CVD), central nervous system, infectious diseases, and others.

Regional Analysis

Globally North America is the largest market for global precision medicine. Europe is the second-largest market for global precision medicine. The near future market for precision medicine will be dominated by the developed regions with developing regions providing a supporting role only. However the developing regions market particularly Asia Pacific will be the fastest growing and is likely to be the key to the future.

Pericarditis Market Expected To Boost During 2019 To 2023

Market Scenario:

Pericarditis is inflammation of the pericardium (the fibrous sac surrounding the heart). Symptoms typically include a sudden onset of sharp chest pain. The pain may also be felt in the shoulders, neck, or back. It generally is better sitting up and worse when lying down or breathing deeply.

The increasing prevalence of cardiovascular diseases such as heart attack & hypertension, favorable reimbursement policies, and increasing preference for minimally invasive procedures are the major drivers propelling market growth. However, the side-effects of anti-inflammatory drugs and the risk of bacterial infections constrain the growth of the market.

The Global Pericarditis Market is expected to register 7.96% CAGR and is anticipated to reach USD 2,741.39 Million by 2023.

Market Dynamics

The prevalence of cardiovascular diseases is found to be increasing over the last decade. This is attributed to the rising incidences of chronic diseases such as obesity and diabetes, which are major risk factors for cardiovascular diseases such as pericarditis, heart attack, and hypertension. As per the American Heart Association, nearly 92.1 million Americans were diagnosed with cardiovascular diseases in 2017. Additionally, it also stated that the prevalence is found to be higher in men than in women. Furthermore, in the same year, more than 92% of the patients exhibited major symptoms of heart diseases such as chest pain, heartburns, and strokes.

Recently, the prevalence of cardiovascular diseases is found to be increasing from the last few years. The American Heart Association stated that in 2015, 3.7% of the Asian population was diagnosed with chronic heart disease, while 21% of the people had hypertension.

Cardiovascular disease is one of the significant chronic disease responsible for a high death toll across the globe. This emphasizes the need for the development of new diagnostics and treatment devices around the world. The market is also affected by the increasing number of people diagnosed with these diseases at an early stage. Therefore, the prevalence of cardiovascular disease would drive the growth of the market during the forecast period.

The market is driven by the increasing number of patients suffering from cardiovascular diseases, thus signifying the need for the development of new technologically advanced devices for monitoring the heart rate. Continuous monitoring of cardiovascular diseases is an important aspect of cardiology. Therefore, the prevalence of pericarditis is increasing with a rise in the prevalence of cardiovascular diseases, fueling market growth.

Segmentation

The global pericarditis market has been segmented into type, application, and end user. 

Based on type, the global market has been segmented acute pericarditis, recurrent pericarditis, and chronic pericarditis.

Based on diagnosis & treatment, the global market has been divided into diagnosis and treatment. The diagnosis segment is further divided into electrocardiogram (ECG), echocardiogram, computerized tomography (CT), X-Ray. The treatment segment is bifurcated into medication (non-steroidal anti-inflammatory drugs (NSAIDs) and colchicine) and surgical treatment.

Based on end user, the global market has been segmented into hospitals & clinics and medical institutes & research laboratories. The hospitals & clinics segment accounted for a market value of USD 840.30 million in 2017.

Key Players

The prominent players in the global pericarditis market are Pfizer Inc., AstraZeneca Plc, Novartis International AG, Allergan plc., and Merck & Co., Inc. are the top five market players in this market. Apart from these, Bayer AG, Reckitt Benckiser Group Plc., PerkinElmer, Inc., FUJIFILM Holdings Corporation, Sanofi, and Johnson & Johnson Services, Inc. are some of the other major players in the global market.

Some of the key strategies followed by the players operating in the global pericarditis market are innovation, product development, acquisition, and expansion.

Regional Analysis

The global pericarditis market, based on region, is segmented into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.

The Americas is estimated to dominate the global pericarditis market during the forecast period. This is attributed to the rising investments in research and development owing to investments in reputed research centers and government institutions and increasing expenditure on healthcare play a vital role in the growth of the regional market. Besides, several research grants are given by governmental agencies.

The European market for pericarditis is expected to be the second-largest during the forecast period. The presence of medical device companies, the rising burden of rheumatoid arthritis (RA), and growing healthcare spending are expected to boost the growth of the market in this region. Additionally, the companies operating in the market are mainly focusing on mergers and acquisition, which is expected to support market growth.

Asia-Pacific is estimated to be the fastest-growing market due to the growing geriatric population, rapid developments in technology. In addition to this, improving healthcare infrastructure has increased the number of research activities in the region. Moreover, in the region, China accounted for a market share of 24.6% in 2017.

Furthermore, the market in the Middle East & Africa is expected to witness slow growth due to limited access to healthcare facilities.

Key Updates

• In July 2017, Pfizer Inc. extended the collaboration with Catalent, Inc., a global provider of advanced delivery technologies and development solutions for drugs, biologics, and consumer health products for the development and manufacture of Advil Liqui-Gels.

• In October 2018, Reckitt Benckiser (RB) launched a 24-hour pain relief patch along with a campaign to educate patients about pain to encourage patients to facilitate pain management.

• In October 2018, FUJIFILM Medical Systems USA, Inc., a provider of diagnostic imaging and medical informatics solutions launched the FCT Embrace wide bore computed tomography (CT) imaging unit in the US, thereby entering into the US computed tomography market.